CJC-1295 No DAC & Ipamorelin Research: DEXA Scan Notes

In research contexts, DEXA scan notes are the body-composition records — bone mineral content, fat mass, and lean soft tissue — produced by dual-energy X-ray absorptiometry and logged as a measured endpoint. CJC-1295 No DAC and ipamorelin appear alongside those records because both are laboratory compounds studied for their action on growth hormone axis signaling, and body composition is one of the standard quantitative endpoints in that field. For a wholesale buyer, though, the useful question is narrower than it first looks. It is not what a scan showed; it is whether the material being studied was identity-confirmed and purity-verified, because an unverified compound makes every downstream measurement uninterpretable. Both compounds are research use only and are not approved drugs.

How dual-energy absorptiometry became a standard endpoint

DEXA works by passing two X-ray energies through tissue and measuring how differently each is attenuated. Because bone mineral, fat, and lean soft tissue absorb those energies in distinguishable proportions, the scanner resolves a three-compartment model of the body rather than a single number on a scale. That is why it displaced hydrostatic weighing and skinfold measurement as the reference method in most body-composition work: it reports regional values — trunk, arms, legs — alongside whole-body totals, and it does so reproducibly enough that the same subject scanned twice on the same machine yields closely comparable results.

Reproducibility is the part that matters when you read a research record. Every scanner carries a precision error, and careful labs establish their own least-significant-change threshold before interpreting any follow-up scan at all. A difference smaller than that threshold is measurement noise, not a finding. Cross-machine comparisons are worse: manufacturers use different calibration standards and software models, so a baseline captured on one system and a follow-up on another can produce apparent change that reflects hardware and algorithm rather than tissue.

Two further limits recur constantly. Lean soft tissue estimates are sensitive to hydration status and glycogen storage, both of which shift on far shorter timescales than tissue remodeling does. And bone mineral density moves slowly — skeletal remodeling proceeds over months — so short observation windows rarely produce interpretable bone data regardless of what is under study. A set of notes reporting dramatic short-window movement in all three compartments at once deserves more scrutiny, not less.

The two compounds, and why the literature pairs them

CJC-1295 No DAC is a modified fragment of growth hormone releasing hormone — the 1-29 sequence, carrying amino acid substitutions intended to slow enzymatic breakdown. It is frequently catalogued as modified GRF(1-29). The No DAC designation is the operative part of the name: the Drug Affinity Complex is a group that, in the DAC-bearing version, binds serum albumin and substantially extends the analog's circulating presence. Without it, the activity profile described in preclinical models is short and pulse-like, which is precisely why investigators studying pulsatile growth hormone axis signaling select this form over the longer-acting one.

Ipamorelin belongs to a different class. It is a pentapeptide that acts as an agonist at the growth hormone secretagogue receptor, GHS-R1a — the ghrelin receptor — and the literature describes it as comparatively selective relative to earlier secretagogues that showed broader endocrine cross-activity. Mechanistically it is not a GHRH analog and does not bind the GHRH receptor.

That divergence is the entire reason the two show up together in experimental designs. Research suggests the GHRH-receptor and ghrelin-receptor pathways converge on the same somatotroph population by different routes, and studies pairing the classes are constructed to probe whether the combined signal is additive, synergistic, or neither. Nothing about that design implies an outcome, and nothing in the published record should be relayed to your own customers as a result. Both compounds remain research use only, are not approved for human use, and are supplied for laboratory work — a boundary that does not soften because a scan record exists somewhere.

What a set of scan notes can and cannot establish

Most of the scan records circulating in this category are not study data. They are self-collected: one subject, one machine, no control arm, no blinding, no pre-registered endpoint, and no independent verification of what was actually in the vial. Whatever they show, they cannot separate compound effect from training load, caloric intake, sleep, seasonal hydration, or simple regression toward the mean after an unusual baseline.

Even well-run studies carry interpretive limits. Small samples produce unstable effect estimates. Unblinded designs invite behavior change in the observed group. Reporting lean mass, fat mass, and bone content together increases the chance that at least one compartment moves by chance alone. And a body-composition endpoint tells you nothing about mechanism — it measures a result, not a pathway.

For a reseller there is a second-order consequence that matters more than the science. Repeating anecdotal scan claims in catalog copy converts someone else's uncontrolled observation into your representation. That is an exposure with no real defense, and it is one of the fastest ways a research-use-only catalog drifts into claims territory. The durable approach is to describe what the compound is and what the research examines, hedge every efficacy statement honestly, and let documentation rather than anecdote carry the credibility.

Documentation is the variable a buyer actually controls

Purity and identity are separate questions, and suppliers blur them constantly. High-performance liquid chromatography separates the contents of a sample and reports the target peak as a percentage of total peak area — that is a purity figure. It does not, by itself, prove that the dominant peak is the sequence printed on the label. Mass spectrometry answers the identity question by confirming molecular weight against the expected sequence. A document offering one without the other leaves half the question open, and for compounds with closely related analogs in circulation, identity confirmation is not optional.

The second thing to check is whether the certificate is batch-specific. A representative certificate — one document reused across production runs — tells you what a lab found once, not what is in the lot arriving at your facility. Ask whether the lot number on the vial appears on the certificate you were sent. Ask whether certificates are published where you can read them before ordering, produced only on request, or sold as a paid add-on. Ask which screens are included beyond identity and purity, and whether the testing lab is independent of the supplier.

The preparation and dosing question, answered plainly

Real Peptides does not publish dosing, titration, reconstitution, or administration guidance for any catalog item, and no legitimate research-use-only supplier should. These are not approved drugs, there are no approved directions for use, and supplying a protocol would recharacterize the product entirely. If a supplier volunteers one, read that as a signal about their compliance posture rather than as a service.

What can be discussed is the arithmetic any laboratory already applies: concentration is mass divided by volume, expressed as milligrams per millilitre. A lyophilized vial is labelled by total peptide mass, and the concentration of any solution prepared from it is a function of that mass and the volume of solvent used. That relationship is the ceiling of what belongs in supplier education. Anything beyond it — measured volumes, draw amounts, device references — is protocol guidance, and it does not appear in Real Peptides materials.

Questions to put to your counsel before reselling

This section is informational and is not legal advice. The regulatory position of research-use-only compounds is not something you can settle by reading a supplier's website, and the analysis shifts with the structure of your business, the nature of your customers, and the jurisdiction you operate in.

The questions worth putting to your attorney in writing: how should research-use-only materials be labelled, stored, and segregated in our facility? What licensing, registration, or professional-board obligations attach to a business that holds or resells these materials where we operate? Does our customer base change that analysis? What records must we retain, and for how long? How should catalog copy be worded so it describes the compound and the research rather than any use? Are there advertising or platform restrictions we should assume apply?

Your state board and your counsel answer those questions; a supplier cannot. What a supplier can do is provide documentation clean enough that your answers are straightforward to evidence when someone asks.

What Real Peptides does differently

Real Peptides supplies CJC-1295 No DAC and ipamorelin, among other growth hormone axis research compounds, through its Wholesale Partner Program, and the program is built around the verification points above rather than around volume pressure. Batches are tested to 99%+ HPLC purity and carry 7-panel batch testing. Certificates of analysis are publicly verifiable — a prospective partner can read the lab results before applying, rather than requesting them after an order or paying for them separately. Fulfillment is US-based within a 5–7 day window, which keeps lead times predictable when you are planning inventory instead of reacting to it.

Pricing is structured rather than negotiated in the dark. Wholesale tiers are disclosed to applicants, so a buyer can model landed cost per unit before committing rather than discovering the real number after a first order. The application itself runs in three steps: submit the business application, complete verification, and receive tier pricing and account access. Every catalog item is research use only and is not sold for human consumption.

Where this leaves a wholesale buyer

Body-composition endpoints are a legitimate and long-standing part of growth hormone axis research, and it is reasonable to want to understand why they recur in the literature around these two compounds. But the scan is not what you are purchasing. You are purchasing a lot of material and the documentation that makes it identifiable and characterizable, and that is the only link in the chain where your diligence changes the outcome.

Buyers comparing this category generally look at CJC-1295 No DAC 10mg and Ipamorelin 10mg side by side, often review Tesamorelin 10mg as a further GHRH-analog research compound, and use the growth factor and tissue signaling research collection to see how these sit relative to the rest of the catalog.

If the documentation standard described here matches how your business already buys, the Wholesale Partner Program application is the natural next step — verification is where the general questions in this article get answered with specifics attached to your account.